Professor Grant McArthur has an international and national reputation as a leader in the medical oncology treatment of melanoma, as demonstrated by the many regular invitations to present at forums of his medical oncology colleagues. He manages a large multi-faceted basic research and clinical program, and has excellent administrative abilities. He is the Head of the Cancer Therapeutics Program, Director of the Melanoma and Skin Service, sits on Peter MacCallum's Cancer Research executive team and directly manages a complex program of three laboratories: the Molecular Oncology Laboratory, the Translational Research Laboratory and the Cooperative Research Centre for Cancer Therapeutics, a multi-institutional collaborative centre for drug development.
Translational Research Award of the Fondation Nelia et Amadeo Barletta
Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, Dummer R, Garbe C, Testori A, Maio M, Hogg D, Lorigan P, Lebbe C, Jouary T, Schadendorf D, Ribas A, O'Day SJ, Sosman JA, Kirkwood JM, Eggermont AM, Dreno B, Nolop K, Li J, Nelson B, Hou J, Lee RJ, Flaherty KT, McArthur GA; BRIM-3 Study Group. Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation. New England Journal of Medicine. 2011, 364 (26): 207-16.